1. Fig. 5 Maraba induces antitumor T cell immunity.
Maraba induces antitumor T cell immunity. (A) Migration of splenocytes induced by conditioned medium from uninfected or infected 4T1 or EMT6 cells (n = 4 experimental replicates). (B) The same experiment was performed in the 4T1 cell line in the presence of control or blocking antibodies (Ab) (n = 4 experimental replicates; unpaired two-tailed t test with Welch’s correction, *P < 0.05, **P < 0.01, and ***P < 0.001). (C and D) Percentage of cells within 4T1 tumors that stained positive for CD45 as quantified by flow cytometry 10 days (C) or 2 days (D) after Maraba treatment with and without CXCR3-blocking antibodies (n = 5 mice; unpaired two-tailed t test with Welch’s correction, **P < 0.01 and ***P < 0.001). (E) Immunohistological assessment of CD3+ cells in 4T1 tumors at the time of resection in the tumor rechallenge model. Scale bars, 100 μm. (F) Interferon-γ (IFN-γ) ELISPOT (enzyme-linked immunospot) analysis of splenocytes harvested 10 days after treatment from mice treated with Maraba for five consecutive days (n = 3 to 5 mice per group). Restim, ex vivo restimulation with cells. (G) The same experiment was repeated with or without blocking antibodies administered intraperitoneally (n = 5 mice per group; unpaired two-tailed t test, **P < 0.01 and ***P < 0.001). The cells were restimulated ex vivo with EMT6 or 4T1 cells. IFN-αR1, IFN-α receptor 1.
Marie-Claude Bourgeois-Daigneault et al., Sci Transl Med 2018;10:eaao1641
Published by AAAS